pmt3

PMT3 is an international multicenter prospective study that evaluates plasma and urinary monoamine-related biomarkers for prediction of malignancy and underlying germ-line mutations of tumor susceptibility genes in patients with pheochromocytomas and paragangliomas (PPGLs). Profiling of plasma and urinary monoamine-related biomarkers is carried out by state-of-the-art liquid chromatography with tandem mass spectrometry.

The trial is an extension of the PMT study, led by Professors Graeme Eisenhofer and Jacques Lenders at the University of Dresden. The PMT study is a general screening study restricted to 6 clinical centers that enrolls patients with suspicion of PPGLs. PMT3 involves patients with confirmed PPGLs entering phase 3 from the PMT study, but is also now open to enrolment of patients with PPGLs at other centers. The primary requirement for recruitment of patients with PPGLs at other centers is that all such patients must be recruited with written informed  consent under a clinical protocol approved by the local IRB or Ethics Committee (e.g., this is possible under the ENS@T registry and biobanking protocol).

Further detailed information is available in the project outline (download PDF).

If you are interested in becoming a participating center please contact one of the below investigators:

Mariko Sue

Email; mariko.sue@uniklinikum-dresden.de

 Tel:      49 351 358 4595

Prof. Graeme Eisenhofer

Email; graeme.eisenhofer@uniklinikum-dresden.de

Tel:       49 351 358 4595

Prof. Jacques Lenders

Email; J.Lenders@aig.umcn.nl

Tel:       31 24 361 8819